Roxflan

Quick links to important sections

Roxflan

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxflan

Property Description
Active ingredient Amlodipine (INN)
Form Oral Tablet, Oral Suspension
Pharmacological class Calcium Channel Blocker (CCB)
Common use Managing elevated blood pressure (Hypertension)
Origin Synthetic (Dihydropyridine derivative)

What is Roxflan and What is its Composition?

Roxflan is a prescription-only medication primarily used for consistent cardiovascular support. The drug is defined by its sole active ingredient, the substance Amlodipine, which is a synthetic small molecule agent and a dihydropyridine derivative. Roxflan is typically supplied as an oral tablet for oral administration, although alternative liquid suspensions exist. The preparation often uses the stabilized form of the drug, Amlodipine besylate, which is a common salt formulation used to ensure stability and reliable absorption within the solid oral product.

Roxflan's Pharmacological Class and General Purpose

Roxflan belongs to the high-level pharmacological class of Calcium Channel Blockers (CCBs) and functions as a long-acting Antihypertensive Agent. Its core mechanism centers on controlling the movement of calcium ions into the walls of blood vessels. Its role is clinically recognized for supporting individuals with high blood pressure, making it a cornerstone in the daily management of Hypertension. Amlodipine is used for the management of high blood pressure. This classification stems from its general physiological action, which results in vasodilation, or the relaxation and widening of the arteries. Consequently, the general benefit of Roxflan is the consistent maintenance of lower blood pressure and improved oxygen delivery to the heart muscle, helping reduce the heart's workload.

Regulatory References

  1. National Institutes of Health
  2. NIH Review on Amlodipine

What side effects are possible with Roxflan?

Possible side effects and safety information

The official regulatory documentation for Roxflan (Amlodipine) outlines the documented safety characteristics and reported adverse reactions based on their frequency of occurrence in clinical use. These safety profiles are formally classified by government health authorities, such as the European Medicines Agency and the U.S. Food and Drug Administration.


Frequency and System Classification

The most frequently observed adverse reaction, classified as Very Common, is Peripheral Oedema (swelling of the extremities), which is often noted as dose-related. Reactions classified as Common include effects on the Nervous System (e.g., Headache, Dizziness, Somnolence) and the Gastrointestinal System (e.g., Nausea, Abdominal pain). Other common effects are Flushing, Palpitations, and generalized Fatigue. Certain reactions, like headache and flushing, may be more pronounced during the initial phase of treatment.


Serious Reactions and Safety Constraints

Official labeling also documents Rare but clinically significant adverse reactions. These include serious systemic events such as Angioedema, Hepatitis, Pancreatitis, and severe cutaneous adverse reactions like Stevens-Johnson syndrome.

The use of Roxflan is formally contraindicated in individuals with known hypersensitivity to the active substance or any other dihydropyridine derivative. Furthermore, the official safety notes indicate that the drug's clearance is reduced in patients with hepatic impairment and older adults, which results in increased systemic exposure in these groups. For patients with renal impairment, no dose adjustment is generally required based on the regulatory profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Roxflan (Amlodipine) is based strictly on documented clinical manifestations and regulator-mandated emergency actions.

Documented Overdose Presentations and Actions

Domain Official Regulatory Statement
Documented overdose presentations Overdose is clinically manifested by excessive peripheral vasodilation and resultant marked and prolonged systemic hypotension (low blood pressure). Other signs include dizziness, fainting (syncope), somnolence, and potential reflex tachycardia.
Physiological systems affected Cardiovascular system (hypotension, vasodilation, shock) and Central Nervous System (somnolence, dizziness).
Emergency-response statements Active cardiovascular support is required for clinically significant hypotension, including elevation of the extremities and the judicious administration of fluids. No specific antidote is known. Supportive measures such as gastric lavage and activated charcoal administration may be considered.
When immediate medical help is required Seek immediate medical attention or call the Poison Help line. Contact emergency services (911) immediately if the affected individual has collapsed, has trouble breathing, has had a seizure, or cannot be awakened.

Severe Outcomes and Monitoring

Classification Official Regulatory Statement
Severity classification Overdose can lead to shock, non-cardiogenic pulmonary edema, and fatal outcomes.
Overdose-context constraints Active cardiac and respiratory monitoring is mandated for massive overdose, with extended clinical monitoring required due to the long terminal elimination half-life.

Regulatory documents define the Roxflan overdose profile by the physiological consequences of excessive calcium channel blockade, specifically severe systemic hypotension and shock. This manifestation establishes the mandatory requirement to seek immediate medical attention and dictates the specific supportive procedures, such as cardiovascular support and continuous monitoring, that must be initiated in a healthcare setting. The official guidance focuses solely on describing the documented clinical risks and mandated emergency actions.

Therapeutic Uses of Roxflan

Roxflan (Amlodipine) is used to address certain conditions characterized by systemic or localized discomfort. The medication’s primary use is for the long-term management of high blood pressure (Hypertension), and for the symptomatic management of angina pectoris.

Sustained Management of High Blood Pressure (Hypertension)

Roxflan is primarily used for managing the condition of sustained elevated blood pressure in adults and is considered relevant for use in pediatric patients aged six and older. The therapeutic benefit is the consistent maintenance of lower blood pressure, which generally contributes to easing the overall symptom load associated with chronic cardiovascular issues.

Control and Supportive Relief of Angina

The medication is commonly used to help with the prevention and symptomatic management of angina pectoris, or chest discomfort. This applies to both Chronic Stable Angina and Vasospastic Angina. Roxflan provides support that may assist with easing the overall symptom load and helps maintain a sense of functional stability for patients. This supportive use is also applied in the long-term management of patients with documented Coronary Artery Disease (CAD).


Quick Fact: Relief for Anginal Chest Discomfort

Roxflan is commonly used to help with managing the painful, recurring episodes of chest tightness that arise from symptomatic physical discomfort, supporting the patient during difficult episodes and helping to maintain functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Roxflan's eligibility profile is strictly defined by government regulatory documents, outlining populations that are permitted, restricted, or contraindicated for use.

Populations for Whom Use is Contraindicated

The medicine is contraindicated for patients with a known hypersensitivity to the active ingredient, amlodipine, or any dihydropyridine derivatives. Absolute prohibitions also apply to patients with severe hypotension, cardiogenic shock, obstruction of the left ventricular outflow tract (such as high-grade aortic stenosis), and hemodynamically unstable heart failure after acute myocardial infarction.

Age-Related Eligibility and Restrictions

Adults are approved for both hypertension and angina indications. For pediatric patients, Roxflan is approved for hypertension only in children aged 6 to 17 years. Safety and efficacy have not been established in children younger than six years of age.

Condition-Specific Limitations

Patients with hepatic impairment must use Roxflan with caution, as reduced liver clearance may be prolonged. For renal impairment, no dose adjustment is typically required. Regarding pregnancy, safety is not established, and use is only permitted if the therapeutic benefit justifies the potential risk. Use during lactation is generally not recommended by regulatory bodies, given that amlodipine is excreted in human milk.

What should I know about interactions with other medicines?

Roxflan Interactions with other medicines and products

Roxflan's official interaction profile is characterized by several combinations that are strictly restricted or require dose modification, primarily due to its effect on drug metabolism and potential for additive toxicities.

Contraindicated Combinations

Co-administration with the following drug categories is officially contraindicated:

  • Other QT-prolonging medicines (e.g., dofetilide, quinidine, pimozide, ranolazine), as this significantly increases the risk of life-threatening heart rhythm abnormalities.
  • Strong inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, ritonavir), because they greatly increase Roxflan levels in the body by reducing its metabolism.
  • Ergot alkaloids (e.g., ergotamine, dihydroergotamine), due to the risk of increased ergot alkaloid exposure, which can lead to ergotism.

Combinations Requiring Restriction or Adjustment

Official documents mandate specific constraints when Roxflan is used with other medicines:

  • Certain HMG-CoA reductase inhibitors (statins), specifically simvastatin and lovastatin, require a maximum daily dose restriction due to increased risk of muscle toxicity (myopathy/rhabdomyolysis) caused by reduced statin metabolism.
  • Oral benzodiazepines and hypnotics (e.g., oral midazolam, triazolam, alprazolam) require a dose reduction to mitigate the enhanced sedative effects.
  • Gastric pH-increasing agents (e.g., antacids, H2-receptor antagonists, Proton Pump Inhibitors) impair Roxflan absorption. To ensure efficacy, Roxflan must be administered with an acidic beverage when used concomitantly with these agents.

Mechanism of Action

Roxflan's mechanism is defined by its molecular interaction with the contraction mechanism of blood vessels, operating through two primary mechanistic domains that lead to a physiological reduction of circulatory resistance.


Selective Blockade of L-type Calcium Channels

Roxflan's active ingredient, Amlodipine, acts by binding to the voltage-dependent L-type calcium channels embedded in the smooth muscle cells of the arteries. By occupying the dihydropyridine site, the molecule inhibits the influx of extracellular calcium ions ( Ca^2+) into the cell. This blockade limits the molecular signal necessary for muscle shortening.


Decreasing Systemic Vascular Resistance

This molecular blockade prevents the activation of key enzymes like Myosin Light-Chain Kinase ( MLCK), effectively disrupting the excitation-contraction coupling pathway. The resulting relaxation causes the peripheral arteries to widen (vasodilation), which decreases the Total Peripheral Resistance ( TPR). Consequently, the heart's required energy expenditure decreases, resulting in a reduced myocardial workload and lower oxygen demand.

Dosage and Administration Information

How to Use Roxflan

This section outlines the instructions for administering Roxflan (Amlodipine), defining the usage patterns for the medication. It describes the procedural framework and prescribed dosage limits.


Administration Scope

Feature Guideline
Route of administration Oral, available as a tablet or liquid suspension.
Dosing schedule Adult Initial Dose: 5 mg once daily. Adult Maintenance Range: 5 mg to 10 mg once daily. Adult Maximum Dose: 10 mg once daily.
Timing in relation to meals May be taken with or without food.
Population-specific rules A lower initial dose of 2.5 mg once daily is recommended for older adults or patients with hepatic impairment.
Missed-dose rule The missed dose should be skipped if it is closer to the time of the next scheduled dose (e.g., more than 12 hours late).

Instruction Classifications

Classification Standard Pattern
Administration method type Oral
Frequency pattern Daily (Once daily)
Use-context constraints Chronic, long-term administration.

Resulting Procedural Structure

Standard administration sequence:

  • Roxflan is administered orally once daily, independent of food consumption, starting at 5 mg for typical adult initiation.
  • The dose may be increased up to the 10 mg maximum daily limit, but adjustments are typically made over a period of 7 to 14 days.
  • When using the liquid suspension, the dose must be measured precisely using a calibrated measuring device.

Connection to the overall use protocol: The instructions establish Roxflan as a chronic, once-daily oral medication with specific initial and maximum daily dosages. The protocol dictates that any dosage adjustment must be executed deliberately over the designated time interval, anchoring the administration to a predictable, response-based titration schedule. This structure maintains the procedural consistency required for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Roxflan

The evidence base for Roxflan (Amlodipine) largely consists of Randomized Controlled Trials (RCTs), comparative studies, and systematic reviews, which form the basis of clinical evidence evaluation. This research focuses on specific, authorized uses and provides context but not individual predictions about the patterns observed in large groups of patients under controlled conditions.


Evidence for Use in High Blood Pressure (Hypertension) Studies

Research into Roxflan for managing elevated blood pressure primarily includes large-scale, placebo-controlled, and comparative RCTs. These studies monitored blood pressure changes and long-term cardiovascular outcomes in adult patients with hypertension, examining measures such as Systolic and Diastolic Blood Pressure (BP) changes and the occurrence of Major Adverse Cardiovascular Events (MACE). Studies report that research monitored changes measured during the study period; findings describe patterns related to blood pressure outcomes across the populations studied. Long-term trials also monitored patterns concerning the rate of cardiovascular events and all-cause mortality when patients were observed over several years while participating in Roxflan research.


Evidence for Use in Angina Studies

For conditions characterized by fluctuating or episodic manifestations like angina, Roxflan was evaluated in short-term RCTs. These studies explored outcomes related to physical discomfort by measuring changes in the frequency of chest discomfort episodes and physical functional capacity, such as measuring a patient’s exercise capacity. Research describes patterns related to the reported frequency of angina episodes, though the research primarily focuses on symptom-related endpoints and functional measures rather than long-term mortality reduction specifically for this condition.


What is Still Uncertain in the Research Landscape for Roxflan

Certainty remains low for certain aspects. Long-term effects beyond five years are not fully established in dedicated studies for all high-risk subgroups. Evidence quality varies across studies, and some older trials may have had smaller sample sizes. For pediatric patients, follow-up durations were limited, and long-term effects are not fully established compared to the adult data set. Research describes group patterns, not personal outcomes, and does not determine whether an individual will respond similarly.

Key Studies & References

  1. NIH MedlinePlus Overview: Amlodipine
  2. Amlodipine (StatPearls) - Comprehensive NIH Review

Frequently Asked Questions (FAQ)

Common questions about Roxflan (FAQ)


Q: Is Roxflan used for any condition other than what is usually prescribed?

Official regulatory documents state that Roxflan (Amlodipine) is indicated for two main uses: managing high blood pressure (hypertension) and treating specific types of chest discomfort known as chronic stable angina and vasospastic angina. The use of Roxflan for any other conditions is not listed in its primary official indications.


Q: How quickly can a person typically expect to feel the effects of Roxflan?

Official information about how Roxflan works shows that the drug reaches its peak concentration in the bloodstream within 6 to 12 hours after administration. However, the complete effect on lowering blood pressure is typically observed after two weeks of consistent daily use.


Q: Does Roxflan cause weight gain or weight loss?

Official reports from clinical trials indicate that both weight gain and weight decrease have been listed among the reported adverse reactions. One of the most common side effects of Roxflan, which is swelling of the hands or feet (peripheral edema), may also contribute to an increase in body weight.


Q: Can Roxflan be taken at the same time as common over-the-counter pain relievers?

Official regulatory documents do not list specific warnings or restrictions regarding co-administration of Roxflan with common non-opioid, over-the-counter pain relievers, such as acetaminophen or ibuprofen (NSAIDs). The general guidance focuses on specific prescription drug interactions.


Q: Does Roxflan interact with birth control pills?

According to official regulatory information, no interaction has been found between Roxflan and oral contraceptives (birth control pills). This indicates that the drug is not documented to change how effective birth control pills are.


Q: Is Roxflan safe to use for older adults (e.g., those over 65)?

Official information describes that Roxflan is used by older adults, noting that specific considerations and adjustments are necessary. A lower initial dose is recommended because older patients may have reduced organ function, leading to higher levels of the drug remaining in the body.


Q: How does Roxflan affect the liver or kidneys?

Roxflan is processed by the liver, and its clearance may be slowed down in individuals with impaired liver function, a factor noted for cautious use. Conversely, regulatory information indicates that Roxflan does not significantly affect kidney function, and no dose adjustment is typically needed for patients with existing kidney problems.


Q: Is Roxflan considered a controlled substance?

While Roxflan is a medicine that requires a prescription, it is not currently classified as a federally controlled substance. This means regulatory bodies have not identified it as having a significant potential for abuse or dependence, unlike some other types of prescription drugs.


Q: Can Roxflan be taken with herbal supplements, like St. John's Wort?

Roxflan is processed by a specific liver enzyme called CYP3A4. Official warnings caution that any substance, including herbal supplements, which affects the activity of this enzyme could change the levels of Roxflan in the body. While St. John’s Wort is not explicitly named, it is an example of a supplement known to interact with this specific enzyme pathway.


Q: Does Roxflan make you more sensitive to the sun?

The official drug labeling does not list photosensitivity, which is an increased sensitivity to sunlight, as a common or frequent adverse reaction of Roxflan.


Q: What is the estimated 'half-life' of Roxflan in the body?

Pharmacokinetic data in official documents indicate that Roxflan has a long terminal elimination half-life, which is the time it takes for half of the drug to leave the body. For adults with normal organ function, this half-life is approximately 30 to 50 hours.


Q: Are there any specific laboratory tests that need to be done while taking Roxflan?

The official labeling does not require routine laboratory testing for all patients taking Roxflan. However, when Roxflan is taken alongside certain other medicines, such as a statin like Simvastatin, specific monitoring may be advised due to the risk of increased statin-related side effects.


Q: Does alcohol consumption change the way Roxflan works?

Regulatory sources note that both Roxflan and alcohol can independently contribute to lowered blood pressure. Taking them together may lead to additive effects, which could potentially result in increased symptoms like dizziness or lightheadedness.


Q: Is it possible to develop a dependency on Roxflan?

Roxflan (Amlodipine) is not classified by regulatory bodies as a controlled substance. Official labeling does not contain specific warnings about the potential for abuse or the development of physical dependence.


Q: Do emotional changes or mood swings occur while taking Roxflan?

Official reports from clinical trials indicate that certain psychiatric reactions have been observed, although they are uncommon or rare. These reactions include reports of 'mood changes,' 'anxiety,' and 'depression.'


Q: Can Roxflan be crushed, split, or chewed?

Regulatory guidance for some formulations of Roxflan tablets states that the tablets should be swallowed whole. Official instructions state that the tablet forms are not intended to be cut, crushed, or chewed.


Q: How long after stopping Roxflan does it stay in your system?

Because Roxflan has a long half-life, meaning it takes a long time for the body to process and eliminate it, regulatory information indicates that full clearance of the drug from the system typically requires several days after the last dose.


Q: Does Roxflan affect sleep patterns?

Adverse reactions listed in official documents indicate a potential effect on sleep patterns. These reported effects include both 'insomnia' (difficulty sleeping) and 'somnolence' (a state of sleepiness or drowsiness).


Q: What is the purpose of the black box warning on Roxflan's packaging?

Roxflan (Amlodipine) does not currently carry a Black Box Warning in its official labeling, which is a specific regulatory action used for the most serious safety concerns. However, official warnings regarding conditions such as symptomatic low blood pressure and the potential for worsening chest discomfort are included.


Q: Does Roxflan affect the effectiveness of vaccines?

Official regulatory information regarding drug interaction studies does not list any known interaction between Roxflan and vaccines. This means that Roxflan is not documented to affect the effectiveness of immunizations.


Q: Is Roxflan available in different strengths?

According to official regulatory documents, Roxflan tablets are formulated in multiple strengths for oral use. These typically include the 2.5 mg, 5 mg, and 10 mg dosage strengths.


Q: If Roxflan is taken for a long time, does its effectiveness decrease?

Regulatory information on the drug’s performance notes that with long-term, once-daily administration, the effect of lowering blood pressure is generally maintained consistently over a 24-hour period. Studies have supported its effectiveness over long treatment durations.


Q: Why do some people take Roxflan for different lengths of time?

Official indications for Roxflan are for the management of chronic conditions, such as high blood pressure and chronic stable angina. The long-term nature of these conditions generally corresponds to the requirement for continuous, long-term administration as described in the official use context.


Q: Does Roxflan cause dry mouth?

Dry mouth is listed in official reports as one of the less common adverse reactions that were observed during clinical trials of Roxflan.


Q: Are there any known interactions between Roxflan and caffeine?

Regulatory labeling does not contain specific information or warnings about an interaction between Roxflan (Amlodipine) and caffeine.


Q: Does Roxflan affect libido or sexual function?

Official reports from clinical trials indicate that sexual dysfunction (affecting both males and females) has been reported as an adverse reaction. This is generally noted as an uncommon side effect of the medicine.


Q: What should be done in the event of an overdose of Roxflan?

Official warnings regarding overdose indicate that taking too much Roxflan can lead to severe and prolonged low blood pressure, which may result in shock and, in rare instances, fatal outcomes. An overdose can cause excessive widening of the blood vessels and may also result in a very rapid heart rate.


Q: Does Roxflan interact with grapefruit or grapefruit juice?

Despite concerns with similar medications, official regulatory labeling for Roxflan does not list a specific interaction warning or restriction related to the consumption of grapefruit or grapefruit juice.


Q: Can Roxflan worsen existing mental health conditions?

Official reports have documented adverse reactions that are related to mental health, including 'depression,' 'anxiety,' and 'nervousness.' This indicates a potential for mental health-related effects while using the medication.

How should Roxflan be stored and disposed of?

How to Store and Dispose of Roxflan?

The official storage and disposal requirements for Roxflan (Amlodipine) are defined by the product's formulation to maintain chemical stability and integrity.

Mandatory Storage and Protection

Requirement Tablet Formulation Oral Suspension/Solution
Temperature Controlled room temperature (20 C–25 C) Specific formulations require refrigeration (2 C–8 C)
Container Keep in the original container, tightly closed. Keep in the original container, tightly closed.
Environment Protect from light, excess heat, and moisture. Do not freeze (prohibited environment).

Safety and Disposal Rules

Regulatory documents mandate that Roxflan must be kept out of the sight and reach of children and pets at all times. Unused or expired medicine must be disposed of in accordance with local regulations. Official guidance recommends utilizing authorized medication take-back programs available through pharmacies or law enforcement agencies to ensure safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxflan found in:

A-Z Index: